Posttransplantation Therapeutic Rapamycin Concentration Protects Nitric Oxide-Related Vascular Endothelial Function: Comparative Effects in Rat Thoracic Aorta and Coronary Endothelial Cell Culture

Transplantation Proceedings

Volumn 42, Issue 5, 2010, Pages 1923-1930

  Parlar, A ^a   Can, C ^a   Erol, A ^a   Ulker S ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ARGININE; CALCIUM IONOPHORE; INTERLEUKIN 1BETA; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRITE; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; POTASSIUM CHLORIDE; RAPAMYCIN;

ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTICLE; BLOOD VESSEL REACTIVITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORONARY ARTERY; DRUG MECHANISM; ENDOTHELIUM CELL; MALE; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; RAT; THORACIC AORTA; VASCULAR ENDOTHELIUM; VASODILATATION; WESTERN BLOTTING;

ACETYLCHOLINE; ANIMALS; AORTA, THORACIC; ARGININE; BLOTTING, WESTERN; CALCIMYCIN; CELL CULTURE TECHNIQUES; CORONARY VESSELS; ENDOTHELIUM, VASCULAR; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-1BETA; MALE; NITRITES; PHENYLEPHRINE; RATS; RATS, WISTAR; SIROLIMUS; VASODILATION;

EID: 77953666438     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2010.03.134     Document Type: Article

References (26)

1. Weis M., and von Scheidt W. Cardiac allograft vasculopathy: a review. Circulation 96 (1997) 2069
2. Liu Z., Wildhirt S.M., Weismuller S., et al. Nitric oxide and endothelin in the development of cardiac allograft vasculopathy: potential targets for therapeutic interventions. Atherosclerosis 140 (1998) 1
3. Weis M., Wildhirt S.M., Schulze C., et al. Impact of immunosuppression on coronary endothelial function after cardiac transplantation. Transplant Proc 30 (1998) 871
4. Corbin F., Blaise G.A., Parent M., et al. Effect of rapamycin on rat aortic ring vasomotion. J Cardiovasc Pharmacol 24 (1994) 813
5. Milliard S., Silva A., Blaise G., et al. Rapamycin's effect on vasomotion in the rat. Tranplant Proc 30 (1998) 1036
6. Jeanmart H., Malo O., Carrier M., et al. Comparative study of CyA and tacrolimus vs newer immunosupressants mycophenolate mofetil and rapamycin on coronary endothelial function. J Heart Lung Transplant 21 (2002) 990
7. Ramzy D., Rao V., Tumiati L.C., et al. Role of endothelin-1 and nitric oxide bioavailability in transplant-related vascular injury: comparative effects of rapamycin and cyclosporine. Circulation 114 1 suppl (2006) I214
8. Neto Mde M., Di Marco G.S., Casarini D.E., et al. Orally administered rapamycin does not modify rat aortic vascular tone. J Cardiovasc Pharmacol 49 (2007) 96
9. Jabs A., Göbel S., Wenzel P., et al. Sirolimus-induced vascular dysfunction: increased mitochondrial and nicotinamide adenosine dinucleotide phosphate oxidase-dependent superoxide production and decreased vascular nitric oxide formation. J Am Coll Cardiol 51 (2008) 2130
10. Togni M., Windecker S., Cocchia R., et al. Rapamycin-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol 46 (2005) 231
11. Muhlestein J.B. Endothelial dysfunction associated with drug-eluting stents: what, where, when and how. J Am Coll Cardiol 51 (2008) 2139
12. Barilli A., Visigalli R., Sala R., et al. In human endothelial cells rapamycin causes mTORC2 inhibition and impairs cell viability and function. Cardiovasc Res 78 (2008) 563
13. DiJoseph J.F., Fluhler E., Armsrong J., et al. Therapeutic blood levels of sirolimus (rapamycin) in the allografted rat. Transplantation 62 (1996) 1109
14. Piper H.M., Spahr R., Mertens S., et al. Microvascular endothelial cells from the heart. In: Piper H.M. (Ed). Cell Culture Techniques in Heart and Vessel Research (1990), Springer, Berlin, Germany 158
15. 2 production. Inflamm Res 49 (2000) 20
16. Lowry O.H., Rosebrough N.J., Farr A.L., et al. Protein measurement with the folin phenol reagent. J Biol Chem 193 (1951) 265
17. Bories P.N., and Bories C. Nitrite determination in biological fluids by an enzymatic one-step assay with nitrate reductase. Clin Chem 41 (1995) 904
18. Stenton S.B., Partovi N., and Ensom M.H. Rapamycin: the evidence for clinical pharmacokinetic monitoring. Clin Pharmacokinet 44 (2005) 769
19. Waldman S.A., and Murad F. Cyclic GMP synthesis and function. Pharmacol Rev 39 (1987) 163
20. Egleme C., Godfraind T., and Miller R.C. Enhanced responsiveness of rat isolated aorta to clonidine after removal of endothelial cells. Br J Pharmacol 81 (1984) 16
21. Schrepfer S., Deuse T., Sultan K.R., et al. Inhibition of restenosis development after mechanical injury: a new field of application for malononitrilamides?. Cardiology 108 (2007) 128
22. Moncada S., Palmer R.M.J., and Higgs E.A.A. Nitric oxide: physiology, pathopysiology and pharmacology. Pharmacol Rev 43 (1991) 109
23. Ghatta S., Tunstall R.R., Kareem S., et al. Rapamycin causes relaxation of human vascular smooth muscle: a novel action of rapamycin mediated via ATP-sensitive potassium channels. J Pharmacol Exp Ther 320 (2007) 1204
24. 1-adrenergic receptor-stimulated cardiac myocyte hypertrophy but not activation of hypertrophy-associated genes. Circ Res 81 (1997) 176
25. Liu Z., Wildhirt S.M., Weismuller S., et al. Nitric oxide and endothelin in the development of cardiac allograft vasculopathy: potential targets for therapeutic interventions. Atherosclerosis 140 (1998) 1
26. Lewis N.P., Tsao P.S., and Rickenbacher P.R. Induction of nitric oxide synthase in the human cardiac allograft is associated with contractile dysfunction of left ventricle. Circulation 93 (1996) 720